RMD Stock Recent News
RMD LATEST HEADLINES
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apnea (OSA) in the United States over the next three decades due to a variety of factors, including an aging population and increasing body mass index (BMI). The study estimates that by 2050, OSA will affect nearly 77 million U.S. adults, representing a relative1 increase of nearly 35% from 2020 and impacting 46% of adults aged 30-69.
For my first rating of ResMed, I'm calling a buy, agreeing with today's consensus from Wall St. and more confident than the quant system, which said hold. Key upside factors are new business acquisitions and FDA approvals, proven demand momentum so far, and revenue diversification along with strong profit margins in its peer group. RMD is a proven dividend grower over 10 years while also having an attractive balance sheet risk profile with a low D/E ratio.
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, and will retire from the board, not standing for reelection at the 2025 Annual Meeting of Stockholders, scheduled for November 19, 2025.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Resmed Inc RMD reported better-than-expected earnings for the second quarter on Thursday.
RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.
ResMed Inc. (NYSE:RMD ) Q4 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Brett A. Sandercock - Chief Financial Officer Michael J.
The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.